Welcome to Biomarker

How does a scientific breakthrough get from bench to bedside?

Biomarker is a free newsletter exploring how science, medicine and biotech align to deliver next generation therapeutics. What do storied scientists consider to be their most impactful discoveries? Which research questions keep them motivated to come into lab, and who are the most promising young investigators in their fields?

How are biotech CEOs and founders navigating the murky waters of the 2022 and raising capital? What advice do they have for aspiring entrepreneurs or biotech investors?

We are in the midst of an explosion in scientific discovery. Biomarker is a snapshot of the most exciting areas in translational science and medicine, and how scientists, clinicians and entrepreneurs view this work.

What to expect

Published weekly, the newsletter consists of three main components:

i) Deep Dives: landscapes on an emerging area in science, medicine or biotech that I find interesting (longer pieces, published less frequently).

ii) Lab Meetings: interviews with well-known scientists and occasionally industry experts.

iii) Deal Flow: short interviews with founders and management of biotech companies. What got them initially interested in entrepreneurship, and what is it like to be in biotech today? What is their company’s secret sauce and are there any upcoming milestones?

Share Biomarker


Dylan Neel
MD-PhD candidate at Harvard Medical School MPhil Pharmacology University of Cambridge, Harvard College '15
Henry Klingenstein
TechBio investor at Artis Ventures (av.co), Stanford GSB '22, Harvard College '15